Patents by Inventor Paul P. Tamburini

Paul P. Tamburini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150299305
    Abstract: The disclosure provides antibodies that are useful for among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Application
    Filed: July 1, 2015
    Publication date: October 22, 2015
    Inventors: Bruce A. ANDRIEN, JR., Douglas L. Sheridan, Paul P. Tamburini
  • Publication number: 20150247849
    Abstract: Disclosed herein are compositions and methods for screening for novel compounds that bind to polypeptides of therapeutic interest (e.g., polypeptides implicated in, or known to contribute to, the pathogenesis of human disease). In some embodiments, the compounds bind to a component of the human complement cascade such as human complement component C5. In some embodiments, the compounds so identified inhibit complement-mediated activity and are potential drug candidates for treating complement-associated disorders. This disclosure also provides compositions and methods for screening for novel compounds that inhibit complement-mediated activity and may be useful for identifying potential drug candidates for treating patients showing little or no response to the existing therapies for treating complement associated disorders.
    Type: Application
    Filed: September 20, 2013
    Publication date: September 3, 2015
    Inventor: Paul P. Tamburini
  • Patent number: 9107861
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: August 18, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini
  • Patent number: 9079949
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: July 14, 2015
    Assignee: ALEXION PHARMACEUTICALS, INC.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini
  • Publication number: 20150183859
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Application
    Filed: March 13, 2015
    Publication date: July 2, 2015
    Applicant: ALEXION PHARMACEUTICALS, INC.
    Inventors: Russell P. ROTHER, Douglas L. SHERIDAN, Paul P. TAMBURINI, Yuchun ZHANG
  • Patent number: 9011852
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: April 21, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Russell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
  • Publication number: 20140206849
    Abstract: The disclosure relates to engineered antibodies that when administered to a human, exhibit a low level of immunogenicity in the human. The disclosure also relates to methods for generating the antibodies. The engineered antibodies can be derived from, e.g., on-human (e.g., murine) donor antibodies or from chimeric or humanized antibodies that, when chronically administered to a human, are known to, are predicted to, or are expected to, elicit a neutralizing anti-antibody response in the human.
    Type: Application
    Filed: April 29, 2011
    Publication date: July 24, 2014
    Applicant: ALEXION PHARMACEUTICALS, INC.
    Inventor: Paul P. Tamburini
  • Publication number: 20130224187
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Application
    Filed: April 29, 2011
    Publication date: August 29, 2013
    Applicant: ALEXION PHARMACEUTICALS, INC.
    Inventors: Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
  • Publication number: 20110002931
    Abstract: The present disclosure relates to bispecific antibodies that can bind to two or more different epitopes. For example, the bispecific antibodies described herein can bind to two or more different proteins, wherein at least two of the proteins are selected from C5a, C5b, a cellular receptor for C5a (e.g., C5aR1 or C5L2), the C5b-9 complex, and a component or intermediate of terminal complement such as C5b-6, C5b-7, or C5b-8. The bispecific antibodies described herein are useful for, e.g., inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 complex) and/or C5a anaphylatoxin-mediated inflammation (e.g., C5a-mediated chemotaxis of inflammatory immune cells). Accordingly, the bispecific antibodies can be used in methods for treating a variety of complement pathway-associated disorders.
    Type: Application
    Filed: June 22, 2010
    Publication date: January 6, 2011
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventor: Paul P. Tamburini
  • Patent number: 7452859
    Abstract: The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental bikunin, serine protease inhibitor domains, and fragments thereof.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: November 18, 2008
    Assignee: Aerovance, Inc.
    Inventors: Paul P. Tamburini, Gary Davis, Katherine A. Delaria, Christopher W. Marlor, Daniel K. Muller
  • Patent number: 7019123
    Abstract: The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental bikunin, serine protease inhibitor domains, and fragments thereof
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: March 28, 2006
    Assignee: Bayer Corporation
    Inventors: Paul P. Tamburini, Gary Davis, Katherine A. Delaria, Christopher W. Marlor, Daniel K. Muller
  • Publication number: 20030194398
    Abstract: The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental bikunin, serine protease inhibitor domains, and fragments thereof.
    Type: Application
    Filed: October 10, 2001
    Publication date: October 16, 2003
    Inventors: Paul P. Tamburini, Gary Davis, Katherine A. Delaria, Christopher W. Marlor, Daniel K. Muller
  • Patent number: 6583108
    Abstract: The instant invention provides for proteins, polypeptides, nucleic acid sequences, constructs, expression vectors, host cells, pharmaceutical compositions of, and methods for using human placental bikunin, serine protease inhibitor domains, and fragments thereof.
    Type: Grant
    Filed: August 31, 1998
    Date of Patent: June 24, 2003
    Assignee: Bayer Corporation
    Inventors: Paul P. Tamburini, Gary Davis, Katherine A. Delaria, Christopher W. Marlor, Daniel K. Muller
  • Patent number: 5981208
    Abstract: A method useful in the diagnosis of Alzheimer's Disease in a patient in which an amyloid protein precursor (APP) substrate is combined with a sample of cerebrospinal fluid or blood obtained from the patient to be tested, and poteolytic cleavage of the APP substrate is detected. The absence of detectable proteolytic cleavage, or the detection of a substantially lesser degree of proteolytic cleavage, in the presence of the patient's sample compared to that detected when an APP substrate is combined with test samples from control individuals, indicates affliction with Alzheimer's Disease. Convenient test reagents and kits for aiding the diagnosis of Alzheimer's Disease are provided, such as comprising an APP substrate and immunoreagents for detecting a fragment formed by proteolytic cleavage as well as chromogenic APP substrates.
    Type: Grant
    Filed: October 6, 1994
    Date of Patent: November 9, 1999
    Assignee: Bayer Corporation
    Inventors: Paul P. Tamburini, Robert N. Dreyer, Kathryn M. Bausch
  • Patent number: 5296604
    Abstract: The present disclosure describes novel peptidomimetic compounds which contain a novel class of isosteres and which inhibit the proteolytic activity of HIV protease and further describes therapeutic compositions comprising said compounds, a method of treatment for patients having the AIDS virus involving administering a therapeutically effective amount of the novel compounds of the present invention, and a method of preparation for said isosteres.
    Type: Grant
    Filed: May 15, 1992
    Date of Patent: March 22, 1994
    Assignee: Miles Inc.
    Inventors: Rudolf H. Hanko, Thomas Gould, Paul P. Tamburini